Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Jun 20, 2024 9:34am
184 Views
Post# 36097615

RE:Increased Value

RE:Increased Value
Kingpin68 wrote: In this latest release, they did not state if the combination of R and the non cancer drug was better than R alone. Are the non cancer drugs just riding the coat tails of R ? Either way, the patents held by Theralase keep increasing in value many times over in my opinion. I think they will make it to approval, but even in a worst case scenario, the patent portfolio must be worth $1-$2 share, or more ?
It's a no brainer.



In the presented histogram, the first black bar represents a non-therapeutic control (placebo) having been added to Rutherrin, which is essentially using Rutherrin alone.  The other white/black bar sets represent cell kill rates of drug "x" alone (white bars), followed by the cell kill rate after having added drug "x" to Rutherrin (designated by the black bars).  When you compare the first black bar (Rutherrin alone) to the subsequent black bars, you can see that that each drug "x" gets a significant boost in cell kill rate that is more than additive (i.e. greater than the sum of the individual kill rates of using drug "x" and Rutherrin alone).  There seems to be a "synergistic" increase in the cell kill rate, which makes this treatment option potential even more exciting, & that's "without" the use of light/radiation.  This "greater than additive" effect of two drugs used together is the goal of any combo treatment.  This is good news imo : )
<< Previous
Bullboard Posts
Next >>